Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Daratumumab
Treatment for Multiple myeloma
Typical Dosage: 16 mg/kg IV or SC weekly for first few weeks, then every 2-4 weeks
Effectiveness
92%
Safety Score
60%
Clinical Trials
293
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
16 mg/kg IV or SC weekly for first few weeks, then every 2-4 weeks
Time to Effect
1-2 months
Treatment Duration
Years to lifetime
Evidence Quality
HIGHConfidence Score
93%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$8,000
Side Effect Mgmt:$10,000
Total Annual:$198,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$220,000
Cost per Remission
$330,000
Comparison vs Lenalidomide + Dexamethasone (Rd)
Cost Difference
+$70,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Daratumumab Outcomes
for Multiple myeloma
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+90%
Remission Rate
+60%
Common Side Effects
Infusion Reactions
+40%
Fatigue
+30%
Nausea/Diarrhea
+25%
Neutropenia
+30%
Upper Respiratory Tract Infection
+30%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
6 active trials recruiting for Daratumumab in Multiple myeloma
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
NCT06296121RECRUITINGPHASE3
252 participants
INTERVENTIONAL
Chelyabinsk, Russia +13 more
Started: Dec 21, 2023
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
NCT07400744NOT YET RECRUITINGPHASE1
102 participants
INTERVENTIONAL
Started: Mar 1, 2026
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587NOT YET RECRUITINGPHASE1
258 participants
INTERVENTIONAL
Springdale, United States +8 more
Started: May 27, 2026
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
NCT04656951ACTIVE NOT RECRUITINGPHASE2
67 participants
INTERVENTIONAL
Cologne, Germany
Started: Jun 1, 2021
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
NCT04009109ACTIVE NOT RECRUITINGPHASE2
79 participants
INTERVENTIONAL
Bangor, United States +6 more
Started: Oct 21, 2020
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
NCT07085728ACTIVE NOT RECRUITINGPHASE2
74 participants
INTERVENTIONAL
Anchorage, United States
Started: Aug 11, 2025
Completed Clinical Trials
8 completed trials for Daratumumab in Multiple myeloma
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
NCT05679258COMPLETEDPHASE1
172 participants
INTERVENTIONAL
Beijing, China +1 more
Started: Jan 31, 2023
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
NCT02316106COMPLETEDPHASE2
123 participants
INTERVENTIONAL
Little Rock, United States +56 more
Started: May 20, 2015
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.
NCT05306587COMPLETED
40 participants
OBSERVATIONAL
Odense, Denmark
Started: Apr 1, 2022
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03768960COMPLETEDPHASE4
150 participants
INTERVENTIONAL
Ahmedabad, India +15 more
Started: Jun 10, 2019
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NCT02116569COMPLETEDPHASE1
9 participants
INTERVENTIONAL
Nagoya, Japan +1 more
Started: Apr 1, 2014
A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
NCT04121260COMPLETEDPHASE1
21 participants
INTERVENTIONAL
Beijing, China +4 more
Started: Dec 25, 2019
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
NCT02852837COMPLETEDPHASE1
50 participants
INTERVENTIONAL
Beijing, China +4 more
Started: Sep 26, 2016
Daratumumab in Treating Patients With Multiple Myeloma
NCT02944565COMPLETEDPHASE2
28 participants
INTERVENTIONAL
Columbus, United States
Started: Feb 22, 2017
Showing 20 of 305 total trials